Skip to main content
Year archive

Swedish Orphan Biovitrum — 2020 filings

All 44 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2020, sourced directly from the official regulator.

44 Filings
2020 Period
2020 filings (44)
Filing Released Lang
Sobi och Apellis redovisar positiva topline-resultat från fas 3-studien PEGASUS efter 48 veckors behandling med pegcetacoplan vid PNH
Regulatory Filings
2020-12-10 Swedish
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
Earnings Release FY 2020
2020-12-10 English
Positionering för framtida tillväxt samt finansiell uppdatering - Sobis kapitalmarknadsdag 2020
Regulatory Filings
2020-12-10 Swedish
Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020
Regulatory Filings
2020-12-10 English
CHMP har gett ett negativt utlåtande för emapalumab för behandling av primär HLH i Europa
Regulatory Filings
2020-11-13 Swedish
The CHMP has adopted a negative opinion for emapalumab in Europe for the treatment of primary HLH
Legal Proceedings Report
2020-11-13 English
Sobi och Apellis inleder samarbete för global utveckling och kommersialisering utanför USA av systemisk pegcetacoplan för sällsynta sjukdomar med akut behov av nya behandlingar
Regulatory Filings
2020-10-27 Swedish
Sobi and Apellis enter collaboration for global co-development and ex-US commercialisation of systemic pegcetacoplan in rare diseases with urgent need for new treatments
M&A Activity
2020-10-27 Swedish
Earnings Release 2020
Earnings Release Q3 2020
2020-10-22 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q3 2020
2020-10-22 English
Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia
Regulatory Filings
2020-10-09 English
Sobi presenterar topline-resultat från fas-3 studien med avatrombopag för behandling av cytostatikainducerad trombocytopeni
Regulatory Filings
2020-10-09 Swedish
Sobi och Selecta Biosciences presenterar topline-data från fas 2-studien med SEL-212 COMPARE som stödjer potentialen att nå viktig klinisk förbättring hos patienter med kronisk gikt
Earnings Release FY 2020
2020-09-30 Swedish
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
Earnings Release FY 2020
2020-09-30 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2020-09-30 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2020-09-30 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-09-14 English
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Capital/Financing Update
2020-07-28 English
Sobi och Selecta slutför det tidigare annonserade strategiska licensavtalet för SEL-212, en ny, fas 3-klar behandling mot kronisk gikt
Regulatory Filings
2020-07-28 Swedish
Sobi kommer att ansöka om förnyad prövning av emapalumab i Europa efter negativt CHMP utlåtande
Legal Proceedings Report
2020-07-24 Swedish
Sobi will file for a re-examination of emapalumab in Europe following negative opinion by CHMP
Legal Proceedings Report
2020-07-24 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-07-16 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-07-16 English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change
2020-07-15 Swedish
The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme
Transaction in Own Shares
2020-07-15 English
Sobi och Selecta ingår strategiskt licensavtal för SEL-212, en ny, fas 3-klar behandling mot kronisk gikt
M&A Activity
2020-06-11 Swedish
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Capital/Financing Update
2020-06-11 English
Kommuniké från Swedish Orphan Biovitrums (”Sobi”) årsstämma
AGM Information
2020-05-13 Swedish
Bulletin from Swedish Orphan Biovitrum’s (“Sobi”) Annual General Meeting (AGM)
AGM Information
2020-05-13 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-04-29 Swedish
Earnings Release 2020
Earnings Release Q1 2020
2020-04-29 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-04-23 English
Sobi sees strong revenue and EBITA growth in the first quarter 2020
Earnings Release Q1 2020
2020-04-13 English
Sobi ser stark intäkts- och EBITA-tillväxt för första kvartalet 2020
Earnings Release Q1 2020
2020-04-13 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-07 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-07 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2020-04-07 Swedish
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2020-04-07 English
Sobi to initiate a clinical study to evaluate whether anakinra and emapalumab may relieve complications associated with severe COVID-19 disease
Regulatory Filings
2020-03-18 English
Sobi kommer att initiera en klinisk studie för att utvärdera om anakinra och emapalumab kan lindra komplikationer associerade med allvarlig COVID-19-sjukdom
Regulatory Filings
2020-03-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-13 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report FY 2019
2020-02-13 English
Sobi’s full year 2019 revenue and EBITA higher than previous estimates
Earnings Release FY 2019
2020-01-16 English
Sobis intäkter och EBITA för helåret 2019 högre än tidigare estimat
Earnings Release FY 2019
2020-01-16 Swedish